Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 18, Issue 5, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2022.2055417
Keywords
Glioblastoma; immunotherapy; chimeric antigen receptor (CAR) T cell; oncolytic virus
Categories
Funding
- Science and Technology Department of Sichuan Province, P.R. China [2017SZ0015]
- National Natural Science Foundation of China [82073404]
Ask authors/readers for more resources
Glioblastoma is a common and aggressive form of brain tumor with poor prognosis. Immunotherapy has shown promise in treating glioblastoma.
Glioblastoma (GBM) stands out as the most common, aggressive form of primary malignant brain tumor conferring a devastatingly poor prognosis. Despite aggressive standard-of-care in surgical resection and chemoradiation with temozolomide, the median overall survival of patients still remains no longer than 15 months, due to significant tumor heterogeneity, immunosuppression induced by the tumor immune microenvironment and low mutational burden. Advances in immunotherapeutic approaches have revolutionized the treatment of various cancer types and become conceptually attractive for glioblastoma. In this review, we provide an overview of the basic knowledge underlying immune targeting and promising immunotherapeutic strategies including CAR T cells, oncolytic viruses, cancer vaccines, and checkpoint blockade inhibitors that have been recently investigated in glioblastoma. Current clinical trials and previous clinical trial findings are discussed, shedding light on novel strategies to overcome various limitations and challenges.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available